Ultragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting
September 16 2016 - 8:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical
company focused on the development of novel products for rare and
ultra-rare diseases, today announced that it will host a conference
call on Monday, September 19 at 11am ET during which Emil D.
Kakkis, M.D., Ph.D., Chief Executive Officer and President, will
discuss results of the KRN23 studies being presented at the
American Society for Bone and Mineral Research (ASBMR) 2016 Annual
Meeting.
The live and replayed webcast of the call will be available
through the company's website at
http://ir.ultragenyx.com/events.cfm. To participate in the live
call by phone, dial 855-797-6910 (USA) or 262-912-6260
(international) and enter the passcode 83882106. The replay of the
call will be available for one year.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company
committed to bringing to market novel products for the treatment of
rare and ultra-rare diseases, with a focus on serious, debilitating
genetic diseases. Founded in 2010, the company has rapidly built a
diverse portfolio of product candidates with the potential to
address diseases for which the unmet medical need is high, the
biology for treatment is clear, and for which there are no approved
therapies.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s
website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Ryan Martins
844-758-7273
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024